Clinical Trials - Household Contacts

• IMPAACT 2034 - Phase I Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis

  Study Location: India

  Eligibility: Ages Eligible for Study: up to 17 Years (Child ) Sexes Eligible for Study: Female Accepts Healthy Volunteers: No

  Enrollment: Open

  Read More

• A5300B/I2003B/PHOENIX, Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients

  Study Location: India

  Eligibility: Men and women age greater than or equal to 18 year

  Enrollment: Open

  Read More